Plasma Aldosterone and Atrial Mitochondrial Functions of Patients Undergoing Cardiac Surgery

References

• Kosmidou I , ChenS, KappeteinAPet al. New-onset atrial fibrillation after PCI or CABG for left main disease: the EXCEL trial. J. Am. Coll. Cardiol., 71(7), 739–748 (2018).
   PubMed Web of Science ®Google Scholar
• Montaigne D , MarechalX, LefebvrePet al. Mitochondrial dysfunction as an arrhythmogenic substrate: a translational proof-of-concept study in patients with metabolic syndrome developing post-operative atrial fibrillation. J. Am. Coll. Cardiol., 62(16), 1466–1473 (2013).
   PubMedGoogle Scholar
• Zhang J , XuS, XuYet al. Relation of mitochondrial DNA copy number in peripheral blood to postoperative atrial fibrillation after isolated off-pump coronary artery bypass grafting. Am. J. Cardiol., 119(3), 473–477 (2017).
   PubMed Web of Science ®Google Scholar
• Alexandre J , SalouxE, ChequelMet al. Preoperative plasma aldosterone and the risk of atrial fibrillation after coronary artery bypass surgery: a prospective cohort study. J. Hypertens., 34(12), 2449–2457 (2016).
   PubMed Web of Science ®Google Scholar
• Nolly MB , CaldizCI, YevesAMet al. The signaling pathway for aldosterone-induced mitochondrial production of superoxide anion in the myocardium. J. Mol. Cell. Cardiol., 67, 60–68 (2014).
   PubMed Web of Science ®Google Scholar
• Matas J , TienSing Young N, Bourcier-LucasCet al. Increased expression and intramitochondrial translocation of cyclophilin-D associates with increased vulnerability of the permeability transition pore to stress-induced opening during compensated ventricular hypertrophy. J. Mol. Cell. Cardiol., 46, 420–430 (2009).
   PubMed Web of Science ®Google Scholar
• Wong R , SteenbergenC, MurphyE. Mitochondrial permeability transition pore and calcium handling. Methods Mol. Biol., 810, 235–242 (2012).
   PubMedGoogle Scholar
• Auré K , MamchaouiK, FrachonP, Butler-BrowneGS, LombèsA, MoulyV. Impact on oxidative phosphorylation of immortalization with the telomerase gene. Neuromuscul. Disord., 17(5), 368–675 (2007).
   PubMed Web of Science ®Google Scholar
• Milliez P , GirerdX, PlouinPF, BlacherJ, SafarME, MouradJJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol., 45(8), 1243–1248 (2005).
   PubMed Web of Science ®Google Scholar
• Petramala L , PignatelliP, CarnevaleRet al. Oxidative stress in patients affected by primary aldosteronism. J. Hypertens., 32(10), 2022–2029 (2014).
   PubMed Web of Science ®Google Scholar
• Ouvrard-Pascaud A , Sainte-MarieY, BénitahJPet al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation, 111(23), 3025–3033 (2005).
   PubMed Web of Science ®Google Scholar
• Messaoudi S , GravezB, TarjusAet al. Aldosterone-specific activation of cardiomyocyte mineralocorticoid receptor in vivo. Hypertension, 61(2), 361–367 (2013).
   PubMed Web of Science ®Google Scholar
• Zhang A , JiaZ, GuoX, YangT. Aldosterone induces epithelial-mesenchymal transition via ROS of mitochondrial origin. Am. J. Physiol. Renal Physiol., 293(3), 723–731 (2007).
   Web of Science ®Google Scholar
• Mayyas F , AlzoubiKH, Van WagonerDR. Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling. Int. J. Cardiol., 168(6), 5135–5142 (2013).
   PubMed Web of Science ®Google Scholar
• Mulder P , MellinV, FavreJet al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur. Heart J., 29(17), 2171–2179 (2008).
   PubMed Web of Science ®Google Scholar
• Kolodziejczyk P , Gromotowicz-PoplawskaA, AleksiejczukM, ChabielskaE, TutkaP, MiltykW. New sides of aldosterone action in cardiovascular system as potential targets for therapeutic intervention. Curr. Drug Targets, 19(16), 1968–1979 (2018).
   PubMed Web of Science ®Google Scholar
• Liu T , KorantzopoulosP, ShaoQ, ZhangZ, LetsasKP, LiG. Mineralocorticoid receptor antagonists and atrial fibrillation : a meta-analysis. Europace, 18(5), 672–678 (2016).
   PubMed Web of Science ®Google Scholar
• Neefs J , vanden Berg NW, LimpensJet al. Aldosterone pathway blockade to prevent atrial fibrillation: a systematic review and meta-analysis. Int. J. Cardiol., 231, 155–161 (2017).
   PubMed Web of Science ®Google Scholar
• Chen S , AcouWJ, KiuchiMGet al. Association of preoperative renin-angiotensin system inhibitors with prevention of postoperative atrial fibrillation and adverse events. A systematic review and meta-analysis. JAMA Netw. Open, 2(5), e194934 (2019).
   PubMed Web of Science ®Google Scholar
• Alexandre J , DolladilleC, DouesnelLet al. Effects of mineralocorticoid receptor antagonists on atrial fibrillation occurrence: a systematic review, meta-analysis and meta-regression to identify modifying factors. J. Am. Heart Assoc., 8(22), e013267 (2019).
   PubMed Web of Science ®Google Scholar
• Alexandre J , OllitraultP, FischerMOet al. Spironolactone and perioperative atrial fibrillation occurrence in cardiac surgery patients: rationale and design of the ALDOCURE trial. Am. Heart J., 214, 88–96 (2019).
   PubMed Web of Science ®Google Scholar
• Arriza JL , WeinbergerC, CerelliGet al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science, 237(4812), 268–275 (1987).
   PubMed Web of Science ®Google Scholar
• Lombès M , AlfaidyN, EugeneEet al. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11B-hydroxysteroid dehydrogenase in the human heart. Circulation, 92(2), 175–182 (1995).
   PubMed Web of Science ®Google Scholar